NCT03377322 is a NA clinical trial of Probiotic Capsule in Parkinson Disease, sponsored by University of Malaya.

Who is sponsoring NCT03377322?

NCT03377322 is sponsored by University of Malaya.

What drugs are being tested in NCT03377322?

Interventions in NCT03377322: Probiotic Capsule, Placebo Capsule.

What condition does NCT03377322 study?

NCT03377322 studies Parkinson Disease.

Is NCT03377322 still recruiting?

NCT03377322 is currently completed. Last updated 30 October 2019.

Last reviewed 2019-10-30 · How we verify

NCT03377322

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Probiotics for Constipation in Parkinson's Disease

Completed NA Last updated 30 October 2019

What this trial tests

NA trial testing Probiotic Capsule in Parkinson Disease in 72 participants. Completed in 31 January 2019.

Timeline

1 December 2017

Primary endpoint
31 January 2019

31 January 2019

Quick facts

Lead sponsor	University of Malaya
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	72
Start date	1 December 2017
Primary completion	31 January 2019
Estimated completion	31 January 2019
Sites	1 location across Malaysia

Drugs / interventions tested

Probiotic Capsule
Placebo Capsule

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

University of Malaya

Who can join

Adults 40 to 85, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a double blinded randomised placebo controlled trial to evaluate the efficacy of probiotics in the treatment of constipation in Parkinson's disease.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases.
Loh JS, Mak WQ, Tan LKS, Ng CX, et al · · 2024 · cited 631× · PMID 38360862 · DOI 10.1038/s41392-024-01743-1
Gut liver brain axis in diseases: the implications for therapeutic interventions.
Yan M, Man S, Sun B, Ma L, et al · · 2023 · cited 165× · PMID 38057297 · DOI 10.1038/s41392-023-01673-4
Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study.
Tan AH, Lim SY, Chong KK, A Manap MAA, et al · · 2021 · cited 165× · PMID 33046607 · DOI 10.1212/wnl.0000000000010998
Does the Gut Microbial Metabolome Really Matter? The Connection between GUT Metabolome and Neurological Disorders.
Marć MA, Jastrząb R, Mytych J. · · 2022 · cited 18× · PMID 36235622 · DOI 10.3390/nu14193967
New Pieces for an Old Puzzle: Approaching Parkinson's Disease from Translatable Animal Models, Gut Microbiota Modulation, and Lipidomics.
Ortega Moreno L, Bagues A, Martínez V, Abalo R. · · 2023 · cited 8× · PMID 37375679 · DOI 10.3390/nu15122775
The gut microbiota influences neurodegenerative diseases through the gut-brain axis: molecular mechanisms and effects on immune function.
Yang J, Song X, Yan S, Li Q, et al · · 2025 · PMID 41601624 · DOI 10.3389/fimmu.2025.1739329

Verify or expand the search:

Other trials of Probiotic Capsule

Trials testing the same drug.

NCT07512557 — Probiotic Research On Safety, Palatability, Efficacy and Receptivity · NA · recruiting
NCT07585474 — Gut Microbiome Response to Long-Haul Travel in Elite Football Players · NA · enrolling by invitation

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other University of Malaya trials

Trials by the same sponsor.

NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
NCT07522463 — Enhancing Attention and Processing Speed Through Home-based Music Rehabilitation Program After Stroke in Malaysia · NA · not yet recruiting
NCT07341802 — Pilot Feasibility Study of a Fall Prevention Exercise Programme for Community-dwelling Older Adults in Nanchang, China · NA · recruiting
NCT07452705 — Small Study Comparing Two Pain Medicines in Teenagers for Pain Control After Scoliosis Corrective Surgery. · NA · not yet recruiting
NCT07369596 — Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03377322 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Malaya
Last refreshed: 30 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03377322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing